#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Safe Long-term Treatment of Nasal Symptoms in Patients with Perennial Allergic Rhinitis

In persistent allergic rhinitis, achieving symptom control is often difficult despite pharmacological treatment and minimizing contact with the allergen. Good efficacy in clinical studies has been shown with combined therapy of intranasal antihistamines with locally acting corticosteroids. The presented study evaluated the long-term safety profile and efficacy of a fixed combination of olopatadine with mometasone.
Source: Life Without Allergic Rhinitis 24. 3. 2022

News N9-GP in Previously Treated Pediatric Patients with Hemophilia B – Extended Follow-up

An analysis of extended treatment with nonacog alfa pegol (N9-GP) in pediatric patients with hemophilia B evaluated the long-term safety and effectiveness of this prophylactic modality.
Source: Hemophilia with Movement 4. 10. 2023

News Effectiveness of the Venetoclax/Rituximab Combination in the Treatment of CLL – 5-Year Follow-Up Data

At the virtual 62nd Annual Meeting of the American Society of Hematology (ASH), updated results of a clinical evaluation of the treatment of patients with refractory/relapsed chronic lymphocytic leukemia (R/R CLL) using venetoclax in combination with rituximab were presented.
Source: Chronic Lymphocytic Leukemia 12. 4. 2021

News Expert Consensus on the Use of Bimekizumab in the Treatment of Plaque Psoriasis and Psoriatic Arthritis

The expert consensus published in February 2024 offers guidance on the use of bimekizumab in the treatment of patients with moderate to severe plaque psoriasis and psoriatic arthritis. It is based on a literature review and an assessment of data from 19 relevant studies. A panel of 9 American dermatologists specializing in psoriasis treatment created and adopted 14 consensus statements and recommendations, 12 of which have a strength of “A”.
Source: Psoriasis 16. 5. 2024

News Position of the Aclidinium-Bromide/Formoterol-Fumarate Combination in COPD Treatment According to Current Recommendations

Dual bronchodilator therapy, which combines long-acting muscarinic antagonists (LAMA) and long-acting β-agonists (LABA), has become an integral part of the treatment for chronic obstructive pulmonary disease (COPD). Growing evidence of the efficacy and safety of the fixed combination of aclidinium-bromide/formoterol-fumarate demonstrates that this treatment meets patient needs and the current GOLD recommendations from 2019.
Source: Treatment of Asthma and COPD 3. 6. 2021

News Risk Factors for Renal Cancer Formation After Kidney Transplantation

German authors in the below-cited work identified modifiable risk factors associated with the development of renal cell carcinoma (RCC) de novo in patients after kidney transplantation.
Source: Kidney Carcinoma 5. 11. 2021

News Hybrid Cooperative Complexes in the Treatment of Osteoarthritis

Intra-articular application of corticosteroids and hyaluronic acid is part of the treatment of osteoarthritis (OA) in patients for whom oral or topical treatment does not provide sufficient response. The following text addresses the lubricating and protective properties of synovial fluid and the related choice of appropriate intra-articular viscosupplementation, with emphasis on innovative molecules with high concentrations of hyaluronic acid and low viscosity.
Source: Pain Management 18. 6. 2024

News Treatment with Osimertinib in Patients with NSCLC After Disease Progression on Previous Therapy – Case Study

We present a case study of a patient with non-small cell lung cancer (NSCLC) with a proven activating mutation of the epidermal growth factor receptor (EGFR) gene, who developed resistance to the first-generation EGFR tyrosine kinase inhibitor (TKI) gefitinib during treatment. After the secondary mutation EGFR T790M was confirmed, osimertinib, a third-generation EGFR TKI, was introduced, resulting in disease regression, which is ongoing. This case study illustrates the significance of the role of osimertinib in the treatment of patients with NSCLC with an activating EGFR mutation, whose disease progresses during treatment with first and second-generation EGFR TKIs due to the emergence of the secondary EGFR T790M mutation.
Source: Lung Cancer 16. 6. 2020

Journal articles Evolution of chronic lymphocytic leukemia treatment over the past 25 years

Author of the article: T. Papajík, R. Urbanová, P. Turcsányi Source: Transfuze a hematologie dnes | 1/2019 29. 3. 2019

News Incidence of Glaucoma or Suspected Glaucoma Within the First Year Post-Lensectomy in Children and Treatment Approach to These Patients

The aim of the study conducted by a team of authors from several American universities was to determine the approximate incidence of glaucoma or suspected glaucoma in children under 13 years old within the first year after lensectomy and to describe the management of care for these patients.
Source: Glaucoma 12. 2. 2020

News Romiplostim in ITP Treatment – Data from German Clinical Practice

Real-world clinical practice data from Germany confirm the beneficial effect and safety profile of romiplostim in patients with immune thrombocytopenia (ITP), both newly diagnosed, persistent, and chronic.
Source: Immune Thrombocytopenia 2. 10. 2023

News Romiplostim in Newly Diagnosed or Persistent ITP

Thrombopoietin receptor agonists (TPO-RA) are now recommended for patients with newly diagnosed immune thrombocytopenia (ITP) or persistent ITP who have failed treatment with corticosteroids or intravenous immunoglobulins. The rationale for these recommendations is documented in a paper whose authors focus on, among other things, the American Society of Hematology (ASH) 2019 guidelines or the European ITP Working Group guidelines. They also summarized published data from clinical trials, real-world practice, etc., regarding the use of the TPO-RA romiplostim in earlier phases of ITP therapy.
Source: Immune Thrombocytopenia 21. 2. 2023

News Long-term Efficacy, Safety, and Tolerability of Normal Human IgG with Facilitated Absorption in Patients with Humoral Immunodeficiency

The treatment of patients with humoral immunodeficiency is long-term and therefore needs to be not only effective but also safe and well-tolerated. Below, we present the outcomes from an Italian real-world clinical practice study evaluating the efficacy, safety, and tolerability of human immunoglobulin for facilitated subcutaneous administration and patient satisfaction with this therapy.
Source: Primary and Secondary Immunodeficiencies 12. 1. 2023

News Change in Mutation Characteristics of NSCLC Detected by Liquid Biopsy – Case Study

Due to changes in mutations during the progression of metastatic non-small cell lung cancer (NSCLC) or to assess treatment response, liquid biopsy is essential for monitoring, as its results can affect the selection of targeted therapy. American authors present the case of a patient with advanced NSCLC initially treated with alectinib due to positive ALK gene rearrangement, whose therapy was switched to sotorasib after disease progression and the finding of the KRAS oncogene G12C mutation in a liquid biopsy.
Source: Lung Cancer 19. 6. 2023

News Levothyroxine Substitution Depending on Patient Genotype

Careful titration of hormone dose leads to optimal dosing of replacement therapy for hypothyroidism. The authors of a cross-sectional study published in the Endocrine Journal examined the impact of polymorphisms in genes for proteins involved in thyroid hormone metabolism on the response to levothyroxine treatment in patients after thyroidectomy.
Source: Thyroid Disorders 7. 6. 2022

News Initiation of Sacubitril/Valsartan After Acute Decompensation of Chronic Heart Failure: The Sooner, the Better

The recently published analysis of data from the extended open-label follow-up of participants in the PIONEER-HF study clearly pointed out the difference in outcomes and prognosis of patients, which is led by the initiation of the combined drug during hospitalization compared to its initiation shortly after discharge.
Source: Chronic Heart Failure and Lipidology 27. 2. 2020

News Results of Levothyroxine Treatment in Pregnant Women with Recurrent Pregnancy Losses with Subclinical Hypothyroidism or Anti-TPO Antibody Positivity

A recent meta-analysis of 15 studies involving a total of 1911 women with a history of recurrent pregnancy losses and positivity for thyroid peroxidase antibodies (TPOAb) or subclinical hypothyroidism showed the benefits of administering levothyroxine on pregnancy outcomes. Women with TPOAb experienced reductions in preterm births, miscarriages, premature rupture of membranes, and fetal growth retardation. Women with subclinical hypothyroidism saw an increase in live births and a decrease in miscarriages.
Source: Thyroid Disorders 16. 10. 2023

News Is the Quality of Life for Patients with Atrial Fibrillation and Heart Failure Comparable When Treated with Bisoprolol and Digoxin?

The British RATE-AF study, published in December 2020 in the JAMA journal, compared the impact on improving the quality of life in patients with permanent atrial fibrillation (AF) and symptoms of heart failure when administering bisoprolol and low-dose digoxin.
Source: Cardiovascular Continuum 21. 9. 2021

News Socio-economic Benefits of Using Obinutuzumab in 1st Line Treatment of Follicular Lymphoma

Pharmacoeconomic analyses remind us that our patients' diseases affect not only themselves or the healthcare system, but also have an impact on the entire society. Patients with follicular lymphoma (FL) are also life partners, parents, relatives, and household members, and last but not least, they are also employees or service workers. How treatment success can reflect in these aspects is suggested by a German study.
Source: Non-Hodgkin Lymphomas and CLL 14. 11. 2020

Journal articles Inherited Thrombophilic Tendencies and Oral Contraceptive Pills

Author of the article: I. Hadačová Source: Česko-slovenská pediatrie | 6/2010 19. 8. 2010

News Which biomarkers can be used for risk stratification in ATTR cardiac amyloidosis?

Effective treatment for patients with transthyretin cardiac amyloidosis requires timely diagnosis and precise risk stratification to identify patients at higher risk of cardiovascular events, heart failure progression, and death. Currently, there are several scoring systems based on commonly available laboratory parameters. Here is a brief overview.
Source: Amyloidosis 11. 7. 2023

News Recommended and Not Recommended Physical Activity for Individuals with Hemophilia

Physical activity is now considered a fundamental prerequisite for maintaining the health of individuals with hemophilia. The World Federation of Hemophilia (WFH) also recommends it to improve fitness and neuromuscular health. Numerous studies have shown that physical activity can help enhance the effectiveness of hemophilia treatment and prevent bleeding episodes. In older individuals, including those with hemophilia, a lack of physical activity increases the risk of developing diabetes, hypertension, dyslipidemia, obesity, and osteoporosis, along with subsequent fractures and complications associated with hemophilia.
Source: Hemophilia with Movement 25. 2. 2021

News How Do Vaccinated MS Patients Fare with COVID-19 Antibodies?

Which disease-modifying drugs for the treatment of multiple sclerosis (MS) reduce the humoral response to COVID-19 vaccination? And does the quantity of post-vaccination antibodies vary depending on the specific vaccine?
Source: Multiple Sclerosis 21. 12. 2021

News Current View on Obstacles in Proper Use of Antibiotics and the Role of Biomarkers in Infection Diagnosis

In the fight against antibiotic resistance, principles for the proper use of antibiotics (ATB) have been introduced globally. The following overview briefly describes the obstacles in leading rational antibiotic therapy and considers the use and benefits of biomarkers.
Source: Anti-Infectives 13. 4. 2023

News Effect of Etanercept on Structural Changes in the Sacroiliac Joint in Patients with Early Axial Spondyloarthritis

Currently, there is limited evidence regarding the effect of tumor necrosis factor inhibitors on structural lesions in patients with early forms of axial spondyloarthritis (AxSpA). The aim of the study presented below, published in January 2021, was to evaluate structural changes in the sacroiliac joint (SIJ) on magnetic resonance imaging (MRI) after 2 years of treatment with etanercept within the clinical study EMBARK in patients with early AxSpA compared to a control cohort not treated with biologics (DESIR) and to assess the relationship between MRI changes and disease activity according to ASDAS.
Source: Arthritis 14. 8. 2021

1 12 13 14 15 16 400
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#